icon
Go back to News
NEWS

GA_P advises Ampersand Capital Partners on an investment in Vivebiotech

icon 5 of December, 2024

Gómez-Acebo & Pombo has advised Ampersand Capital Partners, a private equity firm based in Boston (USA) specialised in the life sciences and healthcare sector, on an investment in the Spanish company Vivebiotech, which develops viral vectors for rare diseases and cancer.

Ampersand’s entry will enable the expansion of the Gipuzkoan biotech company’s lentiviral vector manufacturing capacity and support the execution of its portfolio of pioneering client projects developing innovative cell and gene therapies in vivo and ex vivo.

The team has been formed by David González, Diana Linage, Laura Roda and Nicolas Otero, partner, counsel and associates of the Corporate team; Mariana Díaz-Moro and Carla Fandiño, partner and associate of the Tax team; Irene Fernández-Puyol and Marta Rey, partner and associate of the Public team; Lourdes Escassi, Carmen Abad, Laura Calva and Ignacio Luis Campos; counsel and associates of the Labour team; Bárbara Sainz de Vicuña and Diego Ibañez; counsel and associate of the IP team; Andrew Ward, partner of the Competition team; Isabel Silva, Joaquín Beltrán and Patricia González de Huelbes, associates of the Banking team.

Lawyer mentioned

David González – Partner

Diana Linage – Counsel

See all lawyersicon
See less lawyersicon
Tipology

Deal

Press contact

Sandra Cuesta
Sandra Cuesta
Director of Business Development, Marketing and Communications
Sandra Cuesta
Sandra Cuesta
Director of Business Development, Marketing and Communications
icon
icon

More information about
Gómez-Acebo & Pombo

icon
icon
icon
icon